ClinicalTrials.gov
public full text
Public Domain
A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
This is a multi-center, randomized, double-blind, parallel, placebo-controlled phase 2 clinical study. A total of 403 adult participants with moderate to severe AD are planned to be enrolled to evaluate efficacy, safety, PK characteristics, immunogenicity, and changes in PD characteristics of IBI356.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients#1045405
- A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis#878614
- Safety and Tolerability of BSI-045B in Healthy Adult Subjects and Patients With Atopic Dermatitis#847710
- Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)#1281606
- A First-in-Human PoC Study With BEN2293 in Patients With Mild to Moderate Atopic Dermatitis#1261999
Record · ID 1183365
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive